PepRank

BPC-157

Also: Body Protection Compound 157 · pentadecapeptide · part of 'Wolverine', 'GLOW', 'KLOW' blends

GutOral / Injection

The most-loved healing peptide; strong anecdotes, animal-only data, angiogenesis concern.

Safety tier
Avoid
strict bar
Positive
46%
of 53 reports
Per month
≈ €20–41
injected
Rank
#41
of 61 research peptides

At a glance

Access
Grey market
InjectionFelt in 2 days – 2 weeks
OralFelt in 24 h – 7 days

Builds over days or weeks of regular use rather than with each dose.

Strict case
Pro-angiogenic mechanism with a plausible path to tumour growth and retinal neovascularisation, plus essentially no human safety data. HHS enforcement discretion (29 Oct 2026) is not a safety finding.
Best effects
Faster tendon/ligament/muscle recovery · post-surgical healing · joint and back pain relief · gut lining / reflux / IBD relief
Downsides
Anxiety, insomnia, 'speedy' feeling · anhedonia / low mood in some · headaches, nausea, dizziness · injection-site irritation
Typical use
250-500 mcg/day subQ for 4-8 weeks (often 2x/day near the injury); 500 mcg oral for gut. Users report 500–880 mcg/day (median 500 mcg, n=10).
Stacked with
Stacked with
TB-500: The 'Wolverine' stack, sold as a pre-mixed blend; most injury reports on Reddit are for this pair rather than BPC alone. · GHK-Cu and KPV: 'GLOW' (BPC, TB-500, GHK-Cu) and 'KLOW' (plus KPV) blends; users also add BPC to injectable GHK-Cu to cut the sting. · KPV: Paired for gut and autoimmune inflammation, and used as the non-angiogenic substitute by people who quit BPC.

Safety

Watch
Pro-angiogenic (VEGFR2/eNOS) in animal models: theoretical promotion of existing tumours · Recurring eye/retina reports incl. a choroidal neovascularisation case (anecdotal, plausible via VEGF) · No human safety data beyond tiny pilots (n=2 IV study); FDA CDER recommended against listing · Generic: grey-market endotoxin contamination is common
Tier by safety barStrict AvoidBalanced AvoidEvidence only Caution
  • Seen harm1 of 3
  • Mechanism2 of 3
  • Data gap3 of 3
  • Silent harm3 of 3
  • Product3 of 3
Never if
Active cancer or a history of cancer · Diabetic retinopathy, macular degeneration or other neovascular eye disease · Pregnancy or breastfeeding (no human reproductive data)
Why each score
Seen harm 1/3
FDA's July 2026 review found no published case reports and no serious events in the small human studies; what exists is isolated and confounded: FAERS reports involving blends, TGA hypersensitivity cases it could not split from TB-500, and a first-hand choroidal neovascularisation that needed anti-VEGF injections. FDA PCAC briefing on BPC-157, July 2026: all human exposure, animal toxicology, no case reports ↗Amino Wire: TGA told the Norton inquest of six more anaphylaxis or hypersensitivity cases with CJC-1295/ipamorelin, BPC-157 or TB-500 ↗r/bpc_157: a word of caution (choroidal neovascularisation treated with anti-VEGF) ↗
Mechanism 2/3
Pro-angiogenic in vivo: it raised vessel density and blood-flow recovery in rat ischaemia by activating and up-regulating VEGFR2. No study has tested tumour promotion, and some report the opposite, so the concern is credible but undemonstrated; rat and dog toxicology also showed clotting-time and liver changes. Hsieh et al. 2017: pro-angiogenic BPC-157 acts through VEGFR2 activation and up-regulation (PubMed 27847966) ↗FDA PCAC briefing on BPC-157, July 2026: all human exposure, animal toxicology, no case reports ↗
Data gap 3/3
No human has received it orally, subcutaneously or nasally in a published study; the only human data are about 80 people given it rectally, into a joint or bladder, or IV (two people, both already exposed), in short studies from overlapping authors. No carcinogenicity study exists. FDA PCAC briefing on BPC-157, July 2026: all human exposure, animal toxicology, no case reports ↗Lee & Burgess 2025: IV BPC-157 pilot, n=2, both previously exposed (PubMed 40131143) ↗
Silent harm 3/3
The feared harms, promotion of an existing tumour or retinal neovascularisation, would be silent until advanced, which testimonials cannot reveal. Hsieh et al. 2017: pro-angiogenic BPC-157 acts through VEGFR2 activation and up-regulation (PubMed 27847966) ↗
Product 3/3
Most users inject grey-market vials (oral capsules are second); compounding became legal in the US only with the October 2026 HHS enforcement discretion. AJMC 2026: BPC-157 use rose 33-fold; 35% grey-market, 36% compounding pharmacy ↗Mendias & Awan 2026 preprint: 6,441 grey-market peptide samples, 42-71% failed quality criteria, 15% had endotoxin ↗

User reports

All 55 reports →
Users report
Strong, often dramatic benefits: tendon/rotator-cuff and back pain relief, surgeons 'shocked' at recovery speed, gut/reflux fixes. Acute injuries respond better than chronic ones. Roughly 20-25% report nothing. A notable minority report anxiety, insomnia, anhedonia, headaches and flu-like reactions (often blamed on endotoxin-contaminated vials). There is also a growing cluster of eye complaints (blurry vision, eye pain), including one choroidal neovascularisation case that needed anti-VEGF shots.
Glowing 15Positive 9Mixed 7Nothing 8Negative 4Bad reaction 10
  • @IterIntellectus· · 3115 likesOriginal ↗

    two months ago i injected BPC-157 into my knee. two hours later i walked without pain for the first time since 2019 i've been doing 1-2 mg/day since, local and systemic

    Glowing1-2 mg/day · Injection · 2 months

    knee injury from 2019 squat, failed cortisone and physio

  • @mLaabs1984· · 152 likesOriginal ↗

    Been on it for 8 weeks. Game changer for my shoulder injury. Went from extreme pain when doing a push up to almost normal by week 3.

    Glowing8 weeks

    shoulder injury

  • r/bpc_157· · 186 upvotesOriginal ↗

    I LOVE BPC-157! It has made my joints feel like they did 20 years ago. I was also recently diagnosed with Choroidal Neovascularization (CNV)

    Bad reaction500 mcg/day · Injection · ~3 months

    age 43, family history of type 2 diabetes but normal glucose; improving after stopping

Where to buy

All 29 offers →
Getting it
Research-peptide vials and capsules; since HHS enforcement discretion (29 Oct 2026) US 503A pharmacies and telehealth clinics compound it. Banned in sport by WADA.

A month at 250–500 mcg/day costs ≈ €20–41 from Semax Polska at €2.73/mg.

Cheapest from trusted shops in the EU

ShopPackPricePer mgPer monthTesting
Semax PolskaEU · PL
Trust 4/5Each product shows an Analiza Białek (Wrocław) HPLC report naming its operator Dobre Peptydy sp. z o.o. as the client, with a verification password (Semax 60 mg: 62.18 mg, 99%), and Reddit buyers since 2024 report fast, professional deliveries; the only complaints are about felt effect.Ships to France for €14, 1–5 days.COAs ↗
powder · 10 mg€27€2.73/mg≈ €20–41 a monthThird-party tested
Semax PolskaEU · PL
Trust 4/5Each product shows an Analiza Białek (Wrocław) HPLC report naming its operator Dobre Peptydy sp. z o.o. as the client, with a verification password (Semax 60 mg: 62.18 mg, 99%), and Reddit buyers since 2024 report fast, professional deliveries; the only complaints are about felt effect.Ships to France for €14, 1–5 days.COAs ↗
spray · 20 mg⚠ +5 mg GHK-CuAvoid€39€1.93/mg—Third-party tested

Studies

Evidence
Small human studies — Plus tiny human pilots and case series
3 more studies and 5 sources

Sources

Molecule

Sequence
GEPPPGKPADDAGLV
Length
15 amino acids
Modifications
unmodified (sold as free acid, also arginate/acetate salts)

Sequence

The peptide's chain of amino acids from its start (the N-terminus) to its end, one bead and one letter for each: A alanine, C cysteine, D aspartic acid, E glutamic acid, F phenylalanine, G glycine, H histidine, I isoleucine, K lysine, L leucine, M methionine, N asparagine, P proline, Q glutamine, R arginine, S serine, T threonine, V valine, W tryptophan, Y tyrosine. A modification such as an N-acetyl cap or a C-terminal amide changes how long it lasts in the body. Length tells related peptides apart, from a two-residue dipeptide like carnosine to a 43-residue protein like thymosin beta-4, and predicts neither effect nor safety.

Report grades

Every first-hand Reddit or X report is graded on its own, from glowing through positive, mixed, nothing and negative to bad reaction, and the bar shows how those grades split. Posts that look vendor-adjacent stay on the peptide's page but are left out of the counts.

GlowingPositiveMixedNothingNegativeBad reaction

% positive

The share of a peptide's graded Reddit and X reports that are glowing or positive, vendor-adjacent posts left out. A peptide with few reports is pulled toward the average of all reports, as if it had eight average ones besides its own, so two glowing posts cannot top the list. Peptides rank by this figure, those with no graded report yet after those with one, and Avoid ones after every other entry.

Researcher estimate

No first-hand report of this peptide has been graded yet, so the figure is the researchers' own rating out of 10 from what they read about it. It ranks after every peptide with graded reports until its own arrive.

Safety tier

Each peptide is tiered Clean, Caution or Avoid from its five risk axes under the chosen safety bar. An Avoid peptide carries a real risk of harm, a plausible route to serious harm rather than mere unpleasantness, so it stays listed with the reason but ranks behind every other entry, however good its reviews.

Safety bar

The safety bar sets how much risk it takes to rate a peptide Avoid. Strict: out on any serious mechanism with little human data, or any documented serious harm. Balanced: out on documented serious harm (unless it is obvious, reversible and from a regulated product), or a serious mechanism whose harm would be silent with no human data at all. Evidence only: out only on documented serious harm in humans that is lasting, delayed or from grey-market product.

Seen harm

Documented serious adverse events in humans, from 0 for none despite real exposure to 3 for deaths or several well-documented serious harms. Serious means a hospital or emergency visit or harm lasting weeks, so a headache or a bad night does not count.

Mechanism

A plausible biological route to serious harm at the doses people use, such as growth-factor signalling, hormone-axis suppression, heart or blood-pressure effects or immune activation. It runs from 0 when none is known to 3 when a dangerous pathway has been shown in living animals.

Data gap

How little human safety data exists for the molecule actually sold, from 0 for an approved drug with large trials and years of use to 3 for no human safety data at all. A modified analogue does not inherit its parent's trials.

Silent harm

Whether the feared harm would show quickly or stay hidden, from 0 when it is obvious and goes on stopping to 3 when it is silent and delayed, like tumour promotion or slow organ damage. User reports cannot reveal a harm that takes years to appear, so a high score here limits what good reviews can tell you.

Product

The risk of what people actually buy, from 0 for a regulated pharmacy or supplement product taken by mouth or on the skin to 3 for a grey-market injectable. In one dataset of 6,441 grey-market samples, 42–71% failed basic quality criteria and 15% carried endotoxin; taken by mouth or in the nose, a pack avoids the injection risks.

Evidence

The strongest kind of study behind the peptide's effects, from an approved drug through human controlled trials and small human studies to animal work or nothing of its own. Animal results often fail to carry over to people.

Access

How people get it: as an approved drug, a compounded prescription, an over-the-counter supplement or from the grey market, where nobody checks the vial. The channel decides both the legal position and the risk of a bad batch.

Price per month

Thirty days of the typical dose, from its low end to its high end, priced at the listing a careful buyer would choose: in stock, from a shop scoring 4 of 5 on trust (third-party tested where no score is set), failing that 3, a pure pack before a blend, a European shop first, then the cheapest per mg. The range is the dose's, not the shops'. A per-dose amount counts once a day unless the dose says otherwise. Prices are in euros at ECB rates of 2026-10-29, before shipping; the shop table keeps each listing's price per mg, per gram for bulk supplements. Where no listing can be priced the researchers' own estimate stands in, and says so.

Dose users report

The middle half of the daily doses stated in at least five first-hand reports, vendor posts left out. Where its middle sits more than twice above or below the declared dose, the month is priced at it as well, since what people take is what they pay for.

Shop trust

Each shop's trust on a 1–5 scale, read from its testing and its reputation: 1 for serious red flags (fabricated COAs, scam reports, impersonation, a closed shop), 2 for no public testing, a new shop or active complaints such as seized parcels, 3 for its own COAs or a short track record, 4 for verified third-party testing or a strong reputation, and 5 for third-party batch reports that name the shop, with years of good independent reputation. A shop without a score counts third-party batch testing as 4, its own COAs as 3 and no public tests as 2.

Best value

Within a category or a goal, a peptide that no other beats on both counts: none is rated more positively for the same or a lower monthly price, and none costs less for the same or a higher rating. The chart joins these into the best-value line; the cheapest of them and the best-rated of them both make it, so the line spans the trade-off from cheap to best. Avoid entries never count, and a peptide needs both a % positive and a price to be compared.

Testing

Whether the shop publishes lab results: third-party tested means an independent lab checks each batch, own COA means the shop's own certificate of analysis, and no public tests means neither. A certificate shows purity, not safety.

Added peptide

Some packs sold under one peptide's name hold a second one, such as 5 mg GHK-Cu in a nasal kit, stated only in the description. Sprayed in the nose or injected it reaches the blood like an injection, so it carries the risk of that route and is tiered as the injectable form, whatever its tier on the skin. A pack whose page gives no contents list may hold more than its name.